Prelude Therapeutics (PRLD) CBO reports common stock and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Prelude Therapeutics Inc executive Sean P. Brusky, Chief Business Officer, filed an initial ownership report showing his current equity position in the company. He holds stock options over 300,000, 175,000 and 275,000 shares of common stock, each with a stated exercise price of $0.0000 per share and expirations in 2034, 2035 and 2036.
He also directly owns 100,000 shares of common stock. Footnotes explain these options were granted on May 1, 2024, February 4, 2025 and February 4, 2026 under the 2020 Equity Incentive Plan, with 25% vesting after one year and the remainder vesting monthly over the following three years, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Brusky Sean P.
Role
Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 300,000 shares (Direct);
Common Stock — 100,000 shares (Direct)
Footnotes (1)
- Stock option grant awarded on May 1, 2024 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on May 1, 2025, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Stock option grant awarded on February 4, 2025 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2026, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Stock option grant awarded on February 4, 2026 under the 2020 Equity Incentive Plan. The stock option vests as to 25% of the total shares on February 4, 2027, and thereafter vests as to 1/48th of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
FAQ
What does Sean P. Brusky’s Form 3 filing for Prelude Therapeutics (PRLD) show?
The Form 3 shows Sean P. Brusky’s initial ownership in Prelude Therapeutics. He reports direct holdings of 100,000 common shares and several employee stock options granted under the 2020 Equity Incentive Plan with multi-year vesting schedules and long-dated expirations.
How many stock options does the Prelude Therapeutics (PRLD) Chief Business Officer report on Form 3?
Sean P. Brusky reports three employee stock option positions. These cover 300,000 shares expiring in 2034, 175,000 shares expiring in 2035, and 275,000 shares expiring in 2036, each referencing Prelude Therapeutics common stock as the underlying security.
What are the vesting terms of Sean P. Brusky’s stock options at Prelude Therapeutics (PRLD)?
Each option grant vests 25% of the shares one year after the grant date. The remaining 75% then vests in equal monthly installments over the next 36 months, contingent on Brusky continuing to provide service to Prelude Therapeutics on each vesting date.
What is the exercise price of the employee stock options reported by Sean P. Brusky at Prelude Therapeutics (PRLD)?
The filing lists an exercise price of $0.0000 per share for each employee stock option. This price applies to the options covering 300,000, 175,000, and 275,000 underlying shares of Prelude Therapeutics common stock disclosed in the ownership report.
When do Sean P. Brusky’s employee stock options at Prelude Therapeutics (PRLD) expire?
The reported stock options have long-term expiration dates. The grants tied to 300,000, 175,000, and 275,000 underlying common shares expire on April 30, 2034, February 3, 2035, and February 3, 2036, respectively, if not exercised or otherwise terminated earlier.